


M. Vallejo-Soto a,b,∗, S. Orozco-Simental b

a General Surgery Service, Hospital Ángeles y Star Médica de Querétaro, Querétaro, Mexico

b Clínica de Diagnóstico Servicios Integrados de Imagenología, Querétaro, Querétaro, Mexico

∗Corresponding author. Bernardino del Razo 21-110, Col. Ensenío, C.P. 76178, Querétaro, Qro., Mexico. Telephone and fax: +442 192 3028; cell phone: 442 230 1806. E-mail address: mvallejosoto@gmail.com (M. Vallejo-Soto).

© 2017 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Cavitating mesenteric lymph node syndrome: An uncommon complication of celiac disease

Síndrome del nódulo mesentérico cavitado: complicación infrecuente de la enfermedad celiaca

Celiac disease (CD) is a process with an autoimmune base that affects the small bowel and is triggered by the ingestion of gluten in genetically susceptible individuals. Numerous complications associated with CD have been described, among which cavitating mesenteric lymph node syndrome (CMLNS) stands out for its rarity. Little is known of its etiopathogenesis, and it should be recognized early and differentiated from infections and lymphoma, in particular. We present herein a case of CD with this complication associated with other concomitant diseases with an autoimmune base.

A 52-year-old woman was diagnosed with Sjögren syndrome (SS) and she sought medical attention for altered transaminases and cholestatic enzymes, and positive AMA with positive M2 and elevated IgM. An abdominal ultrasound (US) study and liver biopsy were ordered and treatment with ursodeoxycholic acid at a dose of 14 mg/kg/day was begun due to primary biliary cholangitis (PBC) diagnosis. The patient complained of non-bloody, pasty stools 4-5 times a day over a 6-month period and a consequent weight loss of 8 kg. Physical examination was normal. Weight: 65 kg and height: 172 cm. Body mass index: 23.3. The remarkable laboratory test results were: alanine aminotransferase: 68 (0-31) U/l; aspartate aminotransferase: 113 (0-55) U/l; alkaline phosphatase: 264 (5-36) U/l; GGT: 341 (35-104) U/l; immunoglobulins: IgM: 624 mg/dl (40-230); AMA: 1/604; AMA-M2: positive; and anti-transglutaminase: 160 U (0-20). The US study identified pathologic mesenteric adenopathies with a cystic appearance. Tumor markers were normal. The microbiology study was negative for human immunodeficiency virus and tuberculosis. A thoracoabdominal computerized tomography (CT) scan showed multiple adenopathies in the mesentery > 1 cm, with a rounded cystic aspect and low attenuation in the central area (fig. 1). Colonoscopy was normal and gastroscopy revealed an atrophied duodenal nodular mucosal pattern that was histologically consistent with Marsh Ila stage disease (figs. 2 and 3). Liver biopsy was consistent with stage II PBC.

Once infections (tuberculosis and Whipple’s disease) and Crohn’s disease were ruled out, the main differential diag-

Figure 1 Adenopathies with rounded cystic central zones.
nosis was lymphoma. Given the CD diagnosis, the radiologic characteristics of the adenopathies, and the exclusively mesenteric location, no histologic study was carried out given the low probability of lymphoma. The findings were interpreted as CMLNS and a gluten-free diet (GFD) and early radiologic control were decided upon. At 3 months, the patient had gained 3 kg and the control CT scan showed adenopathy cavitation and reduced size, corroborating the diagnosis (fig. 4).

CMLNS is a very rare complication of CD and its pathogenesis is unknown. It is postulated that an alteration in intestinal permeability could favor massive and chronic exposure to certain antigens, causing ischemic damage from the deposit of immune complexes on the vascular endothelium of the lymph node, and its consequent necrosis. This entity presents with the usual symptoms of CD, mesenteric adenopathies, and sometimes with hyposplenism, and should always be suspected in celiac patients with a poor response to a GFD.

The clinical and radiologic data are essential for diagnosis, and CT is the main study. The initial CT finding is the presence of multiple adenopathies located exclusively in the jejunal-ileal mesentry of various sizes (2-7 cm) and with central areas of low attenuation (density of 30-40 HU or lower) produced by the presence of fluid and/or fat.

Occasionally, fluid-fat levels are observed in the adenopathies, which is a typical radiologic sign of CMLNS. Nuclear magnetic resonance can be useful for viewing fluid-fat levels, using T1 and T2 weighted sequences with fat saturation techniques, even if the fluid-fat levels are not seen in the CT scans. Some authors state that the demonstration of these changes in the adenopathies through magnetic resonance can eliminate the use of other more invasive techniques, such as lymph node puncture.

The main differential diagnoses to be made with CMLNS are infections and lymphoma. Adenopathies from lymphoma have soft tissue attenuation with no cavitation, various lymph node chains are affected, and splenomegaly is common. Infections, such as tuberculosis and Whipple’s disease, can sometimes have non-cavitating, low-attenuation abdominal adenopathies and the laboratory, endoscopic, clinical, and radiologic data are very important for their diagnoses.

Patients that do not clinically improve with a GFD or that have uncharacteristic radiologic findings, must undergo a radiologic or surgery-guided biopsy to obtain a histologic study of the adenopathy.

The pathognomonic CMLNS signs of progressive cavitation of the adenopathies and a decrease in their size are observed after starting a GFD. In addition to the typical CD dietary restrictions, the intensive use of systemic corticoids is sometimes necessary. Even though initial publications described an elevated mortality rate in patients with CMLNS, new studies have reported progression that is similar to that of the rest of celiac patients.

In conclusion, CMLNS is an extremely rare complication of CD that must be differentiated from other clinical entities upon diagnosis and during its progression. Diagnosis can be made through a combination of clinical and radiologic data.

**Financial disclosure**

No financial support was received in relation to this article.
Conflict of interest
The authors declare that there is no conflict of interest.

Acknowledgments
The authors wish to thank the gastroenterologists that participated in the study.

Referencias

D. Ruiz-Clavijo García a,b, A. García de Galdiano Fernández a, B. González de la Higuera Carnicer a, I. Rubio-Marco a, M. Mercado Gutiérrez a

a Digestive Tract Service, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
b Intensive Medicine Service, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain

© 2017 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Erythematous nodules on lower limbs in a kidney transplantation patient

Nódulos eritematosos en miembros inferiores en paciente trasplantada renal

A 42-year-old woman with a past history of kidney transplantation due to probable post-streptococcal glomerulopathy sought medical attention for painful erythematous nodules on her legs of 2-month progression (Figure 1a and b). She had no fever or other symptoms and was referred to the dermatology department. Biopsy was carried out and the report stated fat necrosis of pancreatic origin (Figure 1c and d). The appearance of the nodules coincided with the loss of kidney graft function and re-initiation of hemodialysis. The patient was transferred to the gastrointestinal service due to high amylase and lipase levels (more than triple the normal rate). Upon her admission she had no abdominal pain, jaundice, chyluria, fever, or chills.

Physical examination revealed only dermatosis located on the lower limbs, characterized by pinkish macules and purplish subcutaneous nodules, some of which were oozing oleous matter. The patient’s past history included a kidney transplantation in 1998, secondary hyperparathyroidism, chronic hepatopathy due to HCV with F2 liver fibrosis in the transitional elastography study, and cutaneous B cell lymphoma with no evidence of extracutaneous activity. The patient had undergone parathyroidectomy and cholecystectomy. Her ongoing treatment was: prednisone, mycophenolate, telmisartan, sotalol, darbepoetin, folic acid, atorvastatin, calcium, hydroferol, calcitriol, magnesium, AAS, and pantoprazole.

Complementary tests: Blood chemistry: glucose 106 mg/dl, urea 163 mg/dl, creatinine 3.74 mg/dl, amylase 631 IU/L, lipase 1027 U/L, GOT 53 U/L, GPT 68 U/L, GGT 196 U/L, ALP 80 U/L, LDH 676 U/L, calcium 6.3 mg/dl, CRP 1.07 mg/l, and normal sodium, potassium, and coagulation. Hemogram: Hb 12.1 g/dl, Htc 38.5%, MCV 99 fl, leukocytes 10,050 μl, neutrophils 8,610 μl, and platelets 100,000 μl. PCR CMV was negative. HCV viral load 17,600,000 IU/ml. Autoimmunity and tumor markers were normal (Table 1).

Abdominal CAT, NMR of the pancreas, and MR cholangiography of the bile ducts: consistent with acute interstitial pancreatitis with a low severity index (Figure 2a and b). Endoscopic ultrasound was normal. The patient’s blood chemistry and imaging results were consistent with mild interstitial acute pancreatitis, according to the Atlanta criteria. Exudate cultures from the lower extremities were negative for bacteria and fungi.

Diagnosis was pancreatic panniculitis secondary to idiopathic mild acute pancreatitis (autoimmune, neoplastic, or paraneoplastic pancreatic disease were ruled out) in a kidney transplantation patient with graft function loss and chronic hepatitis from HCV infection.

The patient progressed favorably with analgesic and prednisone treatment and was released on day 20. She presented with the following complications: Enterobacter cloacae.